Cargando…

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR

Detalles Bibliográficos
Autores principales:	Moody, Gordon, Moriguchi, Jodi, Sun, Ji-Rong, McElroy, Patricia, Tan, Hong, Bulliard, Yannick, Pedro, Beltran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649319/ http://dx.doi.org/10.1186/2051-1426-3-S2-P192

Ejemplares similares

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira, et al.
Publicado: (2015)

Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles
por: Freiburghaus, Catja, et al.
Publicado: (2013)

The use of anti-GITR antibody treatment in a murine model of glioblastoma multiforme
por: Miska, Jason, et al.
Publicado: (2015)

Multiple mechanisms for TRAF3-mediated regulation of the T cell costimulatory receptor GITR
por: Li, Hanzeng, et al.
Publicado: (2021)

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Murinization of an anti-GITR IgG2c antibody DTA-1 inhibits immunogenicity-mediated anaphylaxis in C57BL/6J mice
por: Alvarez, Hamsell, et al.
Publicado: (2015)

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
por: Shrimali, Rajeev, et al.
Publicado: (2017)

Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity
por: Bullock, Timothy, et al.
Publicado: (2014)

Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
por: Narumi, Kenta, et al.
Publicado: (2019)

Hyperoxia inhibits alveolar epithelial repair by inhibiting the transdifferentiation of alveolar epithelial type II cells into type I cells
por: McKechnie, S, et al.
Publicado: (2008)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

Steroid responsiveness of peripheral blood T cells derived from steroid sensitive, steroid dependent, and steroid resistant asthmatics, and induction of steroid resistance by costimulatory signal
por: Mori, Akio, et al.
Publicado: (2013)

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
por: Patel, Mira A., et al.
Publicado: (2016)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
por: Weth, R, et al.
Publicado: (2004)

Targeting Costimulatory Pathways in Systemic Sclerosis
por: Boleto, Gonçalo, et al.
Publicado: (2018)

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
por: Cohen, Adam D., et al.
Publicado: (2010)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Self-reported weight loss practices in professional mixed martial artists – preliminary findings
por: La Bounty, Paul, et al.
Publicado: (2013)

Self-reported nutritional supplement usage among professional mixed martial artists – preliminary findings
por: La Bounty, Paul, et al.
Publicado: (2012)

Pharmacokinetics and pharmacodynamics of esomeprazole and ranitidine during continuous venovenous hemodiafiltration
por: Fuhrmann, V, et al.
Publicado: (2013)

Pharmacodynamics and pharmacokinetics of ciprofloxacin during sustained low-efficiency dialysis
por: Olsen, K, et al.
Publicado: (2014)

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
por: Bjorck, Pia, et al.
Publicado: (2015)

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
por: Tigue, Natalie J., et al.
Publicado: (2017)

CD8(+) T Cells: GITR Matters
por: Ronchetti, Simona, et al.
Publicado: (2012)

Cell death and immune regulation: in vivo application of a novel agonistic monoclonal antibody for death receptor Fas
por: Yonehara, S
Publicado: (2003)

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
por: Liu, Huisi, et al.
Publicado: (2022)

Agonistic CD40 antibody induces immune-mediated liver damage and modulates tumor-induced myeloid suppressive cells
por: Medina-Echeverz, Jose, et al.
Publicado: (2014)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose
por: Ji, Yan, et al.
Publicado: (2022)

Pharmacokinetic–pharmacodynamic analysis of human purified C1-esterase inhibitor in patients with sepsis
por: Dolzhenkova, L, et al.
Publicado: (2008)

The Role of GITR/GITRL Interaction in Autoimmune Diseases
por: Tian, Jie, et al.
Publicado: (2020)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qol7sr74jptjmrn4othoihpbhc